Stock Analysis on Net

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Pfizer Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings, including current portion of long-term debt 10,350 2,548 3,985 4,188 2,945 4,040 5,990 645 2,241 3,629 3,888 4,352 2,703 13,363 13,084 16,007 16,195 16,617 10,507 9,410
Trade accounts payable 6,710 5,338 6,081 6,123 6,809 6,267 6,208 5,506 5,578 4,698 4,327 4,064 4,309 4,141 3,872 3,972 4,220 3,942 4,002 4,156
Dividends payable 2,372 2,315 2,303 2,245 2,245 2,249 2,191 2,184 2,162 2,112 2,111 2,104 1,992 1,991
Income taxes payable 2,349 1,898 2,928 1,969 1,587 3,071 3,350 3,177 1,266 4,496 1,742 1,401 1,049 1,430 1,445 1,150 980 1,892 1,536 1,849
Accrued compensation and related items 2,776 2,372 1,972 2,277 3,407 2,852 1,997 2,249 3,332 2,571 2,015 1,985 3,058 2,425 2,042 2,246 2,720 2,369 1,875 1,797
Deferred revenues 2,700 2,204 1,286 1,750 2,520 6,191 3,804 3,108 3,067 3,529 4,291 2,052 1,113
Other current liabilities 20,537 16,776 16,080 20,255 22,567 19,648 23,816 24,583 24,938 20,689 17,217 12,798 11,526 10,683 10,169 10,515 11,085 10,162 12,119 12,211
Current liabilities 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268 42,671 41,803 35,664 26,652 25,920 34,154 32,723 33,890 37,304 36,974 32,030 29,423
Long-term debt, excluding current portion 61,538 61,048 61,356 31,704 32,884 32,629 34,294 35,656 36,195 36,250 35,354 35,347 37,133 49,785 50,529 36,281 35,955 36,044 36,168 35,733
Pension and postretirement benefit obligations 2,167 2,166 2,184 2,179 2,250 2,960 3,257 3,494 3,724 4,303 4,939 5,161 5,411 6,437 6,430 6,535 6,762 6,424 6,292 6,457
Noncurrent deferred tax liabilities 640 1,125 1,232 1,067 1,023 616 558 655 349 328 4,161 4,355 4,063 4,542 5,409 5,268 5,578 6,724 3,180 3,591
Other taxes payable 8,534 8,099 8,052 9,860 9,812 9,701 10,990 11,574 11,331 11,336 11,259 11,759 11,560 11,720 11,468 12,212 12,126 12,504 12,421 14,712
Other noncurrent liabilities 16,540 14,243 13,404 13,009 13,181 12,239 11,312 10,508 9,743 9,201 8,228 6,679 6,669 6,849 6,811 6,812 6,317 6,381 6,183 6,347
Noncurrent liabilities 89,419 86,681 86,228 57,819 59,150 58,145 60,411 61,887 61,342 61,418 63,941 63,301 64,836 79,333 80,647 67,108 66,738 68,077 64,244 66,840
Total liabilities 137,213 117,817 120,875 94,381 101,288 102,459 107,821 101,155 104,013 103,221 99,605 89,953 90,756 113,487 113,370 100,998 104,042 105,051 96,274 96,263
Preferred stock 17 17 18 18 19
Common stock 478 478 478 478 476 476 476 476 473 473 472 472 470 470 471 470 468 468 468 468
Additional paid-in capital 92,631 92,496 92,329 92,153 91,802 91,359 91,183 90,844 90,591 89,973 89,336 89,002 88,674 88,161 87,886 87,680 87,428 87,099 86,963 86,635
Treasury stock (114,487) (114,485) (114,482) (114,473) (113,969) (113,945) (113,939) (113,932) (111,360) (111,358) (111,354) (111,348) (110,988) (110,980) (110,978) (111,010) (110,800) (110,795) (110,786) (110,781)
Retained earnings 118,353 126,411 128,796 131,101 125,656 122,966 116,607 111,193 103,394 102,252 96,346 95,158 96,770 100,284 100,203 101,000 97,670 100,113 94,440 93,388
Accumulated other comprehensive loss (7,961) (7,966) (8,102) (8,289) (8,304) (8,225) (7,119) (6,157) (5,897) (5,649) (4,758) (4,664) (11,688) (12,676) (13,246) (13,131) (11,640) (11,800) (11,535) (10,923)
Total Pfizer Inc. shareholders’ equity 89,014 96,934 99,019 100,970 95,661 92,631 87,208 82,424 77,201 75,691 70,042 68,620 63,238 65,259 64,336 65,026 63,143 65,103 59,568 58,806
Equity attributable to noncontrolling interests 274 270 274 266 255 260 261 261 261 276 273 245 235 236 228 312 304 293 356 352
Total equity 89,288 97,204 99,293 101,236 95,916 92,891 87,469 82,685 77,462 75,967 70,315 68,865 63,473 65,495 64,564 65,338 63,447 65,396 59,924 59,158
Total liabilities and equity 226,501 215,021 220,168 195,617 197,204 195,350 195,290 183,840 181,475 179,188 169,920 158,818 154,229 178,982 177,934 166,336 167,489 170,447 156,198 155,421

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Pfizer Inc. current liabilities decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Pfizer Inc. noncurrent liabilities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Pfizer Inc. total liabilities decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Total Pfizer Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Pfizer Inc. total Pfizer Inc. shareholders’ equity decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.